CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DFGFR2::BICC1FusionPredictiveSupportsSensitivity/ResponseCholangiocarcinomaInfigratinib,PD173074Arai et al., 2014
BCHEK2I157TPredisposingSupportsPredispositionProstate CancerWang et al., 2015
DFGFR2::AHCYL1FusionPredictiveSupportsSensitivity/ResponseCholangiocarcinomaInfigratinib,PD173074Arai et al., 2014
CPOLEMutationPredictiveSupportsSensitivity/ResponseGlioblastomaPembrolizumabJohanns et al., 2016
CPOLEMutationPredictiveSupportsSensitivity/ResponseEndometrial CancerPembrolizumabMehnert et al., 2016
CSQSTM1::NTRK1FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaEntrectinibFarago et al., 2015
CETV6::NTRK3FusionPredictiveSupportsSensitivity/ResponseMammary Analogue Secretory CarcinomaEntrectinibDrilon et al., 2016
CRUNX1Y260*PredisposingSupportsPredispositionAcute Myeloid LeukemiaMichaud et al., 2002
CRUNX1D198YPredisposingSupportsUncertain SignificanceAcute Myeloid LeukemiaBuijs et al., 2001
CMSH2LossPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaAnti-PD-1 Monoclonal Antibody MEDI0680,DurvalumabCastro et al., 2015
CMSH6LOSSPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaAnti-PD-1 Monoclonal Antibody MEDI0680,DurvalumabCastro et al., 2015
CDDX41R164WPredisposingSupportsPredispositionHematologic CancerLewinsohn et al., 2016
CERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
CERBB2G776LPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
CERBB2M774DELINSWLVPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
DPTPRBLoss-of-functionPredictiveSupportsSensitivity/ResponseAngiosarcomaVatalanib,SunitinibBehjati et al., 2014
BBRCA1MutationPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
CKRASG12DPredictiveSupportsSensitivity/ResponseColorectal CancerTherapeutic Tumor Infiltrating LymphocytesTran et al., 2016
CHLA-CCOPY-NEUTRAL LOSS OF HETEROZYGOSITYPredictiveSupportsResistanceColorectal CancerTherapeutic Tumor Infiltrating LymphocytesTran et al., 2016
DATMMutationPredictiveSupportsSensitivity/ResponseMantle Cell LymphomaOlaparibWilliamson et al., 2010
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Squamous Cell CarcinomaInfigratinibNogova et al., 2017
BFGFR3MutationPredictiveSupportsSensitivity/ResponseBladder CarcinomaInfigratinibNogova et al., 2017
CFGFR2::BICC1FusionPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaErdafitinibTabernero et al., 2015
BFGFR2::vFusionPredictiveSupportsSensitivity/ResponseCancerErdafitinibTabernero et al., 2015
BFGFR3::TACC3FusionPredictiveSupportsSensitivity/ResponseCancerErdafitinibTabernero et al., 2015
CFGFR2::BICC1FusionPredictiveSupportsSensitivity/ResponseEndometrial CancerErdafitinibTabernero et al., 2015
DTSC1R1062WPredisposingSupportsUncertain SignificanceTuberous SclerosisHoogeveen-Westerveld et al., 2011
DPTENR173CPredisposingSupportsUncertain SignificanceCancerHan et al., 2000
CPTENR173CPredisposingSupportsPredispositionObsolete PTEN Hamartoma Tumor SyndromeHopman et al., 2012
CVHLExon 1 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLExon 1-2 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLP25L (c.74C>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCybulski et al., 2002
CVHLP59fs (c.173_174insC)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseCho et al., 2009
DGNA11MutationPredictiveSupportsSensitivity/ResponseUveal MelanomaSotrastaurin Acetate,MirdametinibChen et al., 2014
ANF1MutationPredictiveSupportsSensitivity/ResponsePlexiform NeurofibromaSelumetinibDombi et al., 2016
CATMMutationPredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
CPALB2Biallelic InactivationPredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
CMETAmplification AND NOT KRAS MutationPredictiveSupportsResistanceColorectal CancerCetuximab/Irinotecan Regimen,PanitumumabBardelli et al., 2013
DPDGFRAP577SPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAR841KPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAH845YPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAG853DPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DMETAmplification AND NOT KRAS MutationPredictiveSupportsSensitivity/ResponseColorectal CancerCrizotinib,CetuximabBardelli et al., 2013
DVPS37AUnderexpressionPredictiveSupportsResistanceOvarian CancerCetuximabWittinger et al., 2011
BFGFR2AmplificationPredictiveSupportsSensitivity/ResponseStomach CarcinomaFexagratinibPearson et al., 2016
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerCetuximabJeong et al., 2017
BGNASR201PrognosticSupportsPoor OutcomePseudomyxoma PeritoneiPietrantonio et al., 2016
Page 39 of 96
PreviousNext